Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801697 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT00801697: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00801697 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 192 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00801697, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
Interventions
- BIOLOGICAL DNA Vaccine
- BIOLOGICAL DNA Vaccine placebo
- BIOLOGICAL rAd35
- BIOLOGICAL rAd35 placebo
- BIOLOGICAL rAd5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT00801697 record still lists
NCT00801697 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher).
The record links to 0 conditions, and to 5 interventions - of which DNA Vaccine is the first listed.
NCT00801697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00801697 about?
NCT00801697 is a clinical study titled "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector". This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
What is the current status of trial NCT00801697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2009-02. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00801697?
The interventions under investigation include: DNA Vaccine (BIOLOGICAL), DNA Vaccine placebo (BIOLOGICAL), rAd35 (BIOLOGICAL), rAd35 placebo (BIOLOGICAL), rAd5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00801697?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00801697's enrollment target sits among peer trials
192 282nd of 2000 higher than 1,718 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia